

Uganda Impact, Mid-Year 2012

Mid-year 2012, PSI has averted an estimated 112,876 DALYs in Uganda. This is 15% of their own program target for 2012.


UGANDA PROGRAM PERFORMANCE

| | 2012 YTD | % Change from 2011 YTD | % 2012 Program Target | 2012 Program Target |
|-------------------------------------|--------------|--------------------------|-----------------------|---------------------|
| SCALE | | | | |
| ■ DALYs Averted | 112,876 | 32% | 15% | 750,026 |
| ■ Couple Years of Protection (CYP)* | 168,328 | 74% | 43% | 390,548 |
| ■ Burden Averted | 0.6% | | | |
| RELEVANCE | | | | |
| ■ Health Relevance | 60% | ■ 2011 Net Cost per DALY | | \$31 |
| ■ Family Planning Method Mix** | 5 with 2 LTM | ■ 2011 Net Cost per CYP | | \$17 |

* CYPs based on new USAID conversion factors, except IUDs
 ** Target is 4 or more FP modern methods with at least one long-term method

UGANDA

Map



UGANDA HEALTH AREA PERFORMANCE

| Current PSI Product & Service Health Areas | 2012 YTD | | | % of Country Total Burden |
|---|---------------|------------------------|----------------|---------------------------|
| | DALYs Averted | % Change from 2011 YTD | Burden Averted | |
| HIV & STD | 61,833 | 23% | 2.1% | 19.5% |
| Reproductive Health | 44,412 | 70% | 1.2% | 13.1% |
| Malaria | 3,812 | -37% | 0.3% | 10.7% |
| Diarrheal Diseases | 1,466 | 187% | 0.4% | 7.3% |
| Respiratory Infections | 1,354 | -46% | 0.1% | 9.2% |
| Potential 6% increase in relevance with expansion of existing PSI products and services | | | | % of Country Total Burden |
| Tuberculosis | | | | 3.0% |
| Nutritional Deficiencies | | | | 3.4% |


UGANDA

Platform Profile

| | |
|---------------------------------|--------------|
| Population | 33,424,683 |
| Population under 5 | 6,465,275 |
| Women aged 15-49 | 7,297,556 |
| # Platform interventions | 22 |
| # Family planning interventions | 5 with 2 LTM |
| Contraceptive prevalence | 17.9% (2006) |

* Population data from UN Population Division, 2010 revision

PSI RELEVANCE: 2012 DALYS AVERTED YTD COMPARED TO BURDEN OF DISEASE (WHO 2004)*



- **Innovation in Other Health Areas:** Burden from non-communicable diseases and injuries
- **Innovation in Communicable Diseases:** Additional communicable burden not addressed by PSI
- **Expansion:** % disease burden targeted by existing PSI products and services not in use by country platform
- **Health Relevance:** % disease burden targeted by current country platform products and services
- **Burden Averted:** % DALYs averted by PSI in 2012 YTD as proportion of WHO (2004) Burden of Disease DALYs
 - In 2012 YTD, 0.5% of global DALYs were averted by PSI.
 - In Uganda, 0.6% of DALYs were averted by PSI in 2012 YTD.

Note: Updated WHO Global Burden of Disease estimates produced by IHME are anticipated late 2012


UGANDA PRODUCTS & SERVICES DALYS AVERTED (from highest to lowest DALYs averted)

| Products | 2012 YTD DALYs | % Change from 2011 YTD | 2012 YTD # Distributed | 2012 Targeted Distribution | % of 2012 Target | 2011 unit COGS | 2012 YTD CYPs |
|-------------------------|----------------|------------------------|------------------------|----------------------------|------------------|----------------|----------------|
| Basic Care Package | 42,865 | 163% | 5,446,363 | 17,336,500 | 31% | \$0.10 | |
| Condom | 24,216 | -22% | 3,677,740 | 8,000,000 | 46% | \$0.02 | 30,648 |
| IUD Insertion | 13,671 | 132% | 16,588 | 36,000 | 46% | \$1.27 | 58,058 |
| IUD Distribution | 11,172 | 761% | 27,699 | 5,000 | 554% | \$1.27 | 50,474 |
| Misoprostol | 5,086 | 193% | 216,063 | 200,000 | 108% | \$0.17 | |
| Implant 5 Insertion | 4,838 | 154% | 7,382 | 11,760 | 63% | \$21.20 | 28,052 |
| Implant 3 Distribution | 2,692 | -1065% | 5,579 | | | \$21.20 | 13,948 |
| Free Condom | 2,562 | -87% | 389,100 | 3,000,000 | 13% | \$0.02 | 3,243 |
| Malaria PPT (ACT) | 2,095 | -61% | 28,962 | 417,391 | 7% | \$0.57 | |
| Malaria RDK | 1,714 | 146% | 25,721 | 22,000 | 117% | \$0.39 | |
| Free Female Condom | 1,476 | 272% | 234,433 | 500,000 | 47% | \$0.24 | 1,954 |
| Pneumonia PPT | 1,354 | -46% | 6,531 | 6,500 | 100% | \$0.08 | |
| Injectable 3 | 876 | * | 14,260 | 43,268 | 33% | \$0.85 | 3,565 |
| Water Treatment Tablets | 579 | 87% | 2,110,910 | 6,000,000 | 35% | \$0.06 | |
| ORS | 351 | 1727% | 23,750 | 25,495 | 93% | \$0.11 | |
| Zinc | 240 | 438% | 35,000 | 22,784 | 154% | \$0.02 | |
| OCs | 240 | * | 14,175 | 22,641 | 63% | \$0.33 | 945 |
| Clean Delivery Kit | 207 | 68% | 21,180 | 50,000 | 42% | \$1.23 | |
| Diarrhea Treatment Kit | 170 | 190% | 4,679 | 6,800 | 69% | \$0.24 | |
| PUR | 127 | 60% | 926,411 | 2,000,000 | 46% | \$0.06 | |
| LLINs | 3 | 11% | 10 | 1,500,000 | 0% | | |
| Implant 5 Distribution | -3,657 | 117% | 110 | | | \$21.20 | (22,557) |
| Implant 3 Insertion | 0 | -100% | - | 5,040 | 0% | \$21.20 | |
| Immunization | 0 | * | - | 15,000 | 0% | | |
| Iron Folic Acid Tablet | 0 | * | - | 310,859 | 0% | | |
| Malaria PPT (Non-ACT) | 0 | * | - | 17,582 | 0% | | |
| Male Circumcision | 0 | * | - | 5,500 | 0% | | |
| Nevirapine | 0 | * | - | 1,000 | 0% | | |
| STI Kit | 0 | * | - | 3,000 | 0% | | |
| TB DOTS | 0 | * | - | 1,000 | 0% | | |
| VCT | 0 | * | - | 70,000 | 0% | | |
| VSC | 0 | * | - | 8,160 | 0% | | |
| Total | 112,876 | 32% | | | | | 168,328 |

* Product was not distributed in 2011

** DALYs averted and CYPs provided may be negative for products distributed in cases where PSI has distributed and inserted the same product. This is because DALYs averted and CYPs are calculated separately for products that are distributed and inserted; to avoid double counting, insertion DALYs and CYPs are subtracted from distribution.

PROGRESS TOWARD UGANDA 2012 PROGRAM DISTRIBUTION TARGETS (% of 2012 Target)



* Targets are set by # of products distributed.